MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-17-2025
Zynex Operating Income 2011-2026 | ZYXI
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Zynex
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.99 M | 10.8 M | 22.9 M | 22.4 M | 10.2 M | 11.1 M | 10.4 M | 8.94 M | 640 K | -2.48 M | -5.7 M | -7.6 M | 2.74 M | 3.1 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 22.9 M | -7.6 M | 6.67 M |
Quarterly Operating Income Zynex
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -44 M | -10.3 M | -13.1 M | - | 3.8 M | 2.23 M | 525 K | - | 5.48 M | 2.71 M | 284 K | - | 6.56 M | 4.36 M | 1.91 M | 11.6 M | 8.05 M | 3.81 M | -1.08 M | 2.3 M | 1.41 M | 4.08 M | 2.46 M | 3.73 M | 2.5 M | 2.58 M | 2.26 M | 2.88 M | 2.82 M | 2.72 M | 1.96 M | 3.59 M | 2.94 M | 1.93 M | 483 K | 518 K | 622 K | -150 K | -350 K | - | -226 K | -363 K | -772 K | - | 412 K | -5.42 M | -1.29 M | - | -1.07 M | -2.56 M | -362 K | - | 712 K | 932 K | 486 K | - | 1.1 M | 899 K | -139 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 11.6 M | -44 M | 323 K |
Operating Income of other stocks in the Medical devices industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Apollo Endosurgery
APEN
|
-31.4 M | - | - | $ 475 M |  USA |
 |
Aziyo Biologics
AZYO
|
-26.9 M | - | 1.37 % | $ 20.5 M | USA |
 |
AdaptHealth Corp.
AHCO
|
90.9 M | $ 13.27 | -1.35 % | $ 1.79 B | USA |
 |
Allied Healthcare Products
AHPI
|
-1.27 M | - | 3.58 % | $ 2.21 M | USA |
 |
Avinger
AVGR
|
-16.6 M | - | -20.74 % | $ 369 K | USA |
 |
BIOLASE
BIOL
|
-17.9 M | - | -13.19 % | $ 166 K | USA |
 |
Axonics Modulation Technologies
AXNX
|
-64.9 M | - | - | $ 3.31 B | USA |
 |
BioSig Technologies
BSGM
|
-71.1 M | - | 37.08 % | $ 85.7 M | USA |
 |
EDAP TMS S.A.
EDAP
|
-20.5 M | $ 3.3 | -0.15 % | $ 124 M |  France |
 |
Conformis
CFMS
|
-46.3 M | - | - | $ 16.4 M | USA |
 |
Electromed
ELMD
|
9.66 M | $ 25.74 | - | $ 218 M | USA |
 |
Cardiovascular Systems
CSII
|
-35.8 M | - | 0.15 % | $ 844 M | USA |
 |
Cytosorbents Corporation
CTSO
|
-14.7 M | $ 0.64 | 6.67 % | $ 39.8 M | USA |
 |
ClearPoint Neuro
CLPT
|
-24.2 M | $ 10.74 | -3.07 % | $ 304 M | USA |
 |
Dynatronics Corporation
DYNT
|
-2.45 M | - | 14.99 % | $ 929 K | USA |
 |
Globus Medical
GMED
|
480 M | $ 89.45 | -1.39 % | $ 12.1 B | USA |
 |
Eargo
EAR
|
-112 M | - | - | $ 10.2 M | USA |
 |
Second Sight Medical Products
EYES
|
-27.6 M | - | -0.97 % | $ 54.4 M | USA |
 |
Helius Medical Technologies
HSDT
|
-12.4 M | $ 2.07 | -0.48 % | $ 1.26 M | USA |
 |
GBS
GBS
|
-10.6 M | - | -0.57 % | $ 7.12 M | USA |
 |
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M |  Canada |
 |
Butterfly Network
BFLY
|
-74.4 M | $ 5.07 | -1.65 % | $ 1.07 B | USA |
 |
Pulmonx Corporation
LUNG
|
-53.7 M | $ 1.23 | 0.41 % | $ 50 M | USA |
 |
OrthoPediatrics Corp.
KIDS
|
-39.2 M | $ 14.87 | -1.78 % | $ 349 M | USA |
 |
Delcath Systems
DCTH
|
660 K | $ 10.31 | -2.27 % | $ 369 M | USA |
 |
Orthofix Medical
OFIX
|
-81.4 M | $ 11.62 | -2.43 % | $ 460 M |  Curacao |
 |
IRIDEX Corporation
IRIX
|
-2.57 M | $ 1.03 | -0.96 % | $ 17.4 M | USA |
 |
Insulet Corporation
PODD
|
474 M | $ 180.5 | -1.3 % | $ 12.7 B | USA |
 |
CONMED Corporation
CNMD
|
103 M | $ 36.61 | -0.49 % | $ 1.14 B | USA |
 |
LivaNova PLC
LIVN
|
199 M | $ 60.23 | -1.73 % | $ 3.29 B |  Britain |
 |
Inspire Medical Systems
INSP
|
51 M | $ 54.6 | -0.9 % | $ 1.6 B | USA |
 |
LENSAR
LNSR
|
-24.6 M | $ 5.29 | -1.12 % | $ 63.3 M | USA |
 |
Integer Holdings Corporation
ITGR
|
221 M | $ 83.71 | -1.1 % | $ 2.91 B | USA |
 |
Invacare Corporation
IVC
|
-80.5 M | - | - | $ 24.7 M | USA |
 |
Edwards Lifesciences Corporation
EW
|
1.26 B | $ 81.55 | -0.89 % | $ 47.7 B | USA |
 |
Sintx Technologies
SINT
|
-10.7 M | $ 2.13 | -0.7 % | $ 5.91 M | USA |
 |
Stryker Corporation
SYK
|
4.89 B | $ 315.23 | -1.95 % | $ 120 B | USA |
 |
MiMedx Group
MDXG
|
63.9 M | $ 3.37 | -0.88 % | $ 498 M | USA |
 |
Tactile Systems Technology
TCMD
|
29.3 M | $ 22.99 | -2.46 % | $ 526 M | USA |
 |
TELA Bio
TELA
|
-33.8 M | $ 0.77 | -1.28 % | $ 36.1 M | USA |